| Dermatitis |
1 |
1 |
| Child |
0 |
0.85 |
| Adolescent Medicine |
0 |
1 |
| Pediatric Dermatology |
0 |
0.85 |
| Allergic Conjunctivitis |
0 |
0.35 |
| Bacterial Conjunctivitis |
0 |
0.35 |
| Viral Conjunctivitis |
0 |
0.35 |
| Ocular Allergy |
0 |
0.31 |
| Minnesota |
0 |
0.28 |
| Oregon |
0 |
0.28 |
| Atopic Dermatitis |
0 |
1 |
| Biologic Therapy |
0 |
1 |
| Health Care Reform |
0 |
0.16 |
| Dorsum |
0 |
0.14 |
| Food and Drug Administration (FDA) |
0 |
0.14 |
| Immunization |
0 |
0.14 |
| Outpatient Clinic |
0 |
0.14 |
| COVID-19 Vaccine |
0 |
0.11 |
| Atopic Keratoconjunctivitis |
0 |
0.1 |
| Patient Safety |
0 |
0.1 |
| Upper Respiratory Tract Infection |
0 |
0.1 |
| Adverse Effects |
0 |
0.07 |
| Cyclosporine |
0 |
0.07 |
| Dermatoses |
0 |
0.07 |
| Eczema |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Interleukin |
0 |
0.07 |
| Keratoconjunctivitis |
0 |
0.07 |
| Nasopharyngitis |
0 |
0.07 |
| Pain |
0 |
0.07 |
| Phototherapy |
0 |
0.07 |
| Quality of Life |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Respiratory Tract |
0 |
0.07 |
| Severity Index |
0 |
0.07 |
| COVID-19 |
0 |
0.06 |
| Headache |
0 |
0.06 |
| Revenue and Practice Management |
0 |
0.06 |
| Vaccines |
0 |
0.06 |